- Home
- > Media & Investors
- > Media Relations
- > Press Releases
Press Releases
-
2019.09.17
PDF (304KB)
- Mitsubishi Tanabe Pharma and Daiichi Sankyo announce alliance for ALS treatment agent edaravone in Brazil
-
2019.09.12
PDF (168KB)
- Daiichi Sankyo Announces Launch of Oxycodone Extended Release Tablets NX “Daiichi Sankyo” for Sustained Cancer Pain Treatment in Japan
-
2019.09.10
PDF (105KB)
- Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer
-
2019.09.10
PDF (115KB)
- Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung Cancer
-
2019.09.09
PDF (96KB)
- Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2 Positive Metastatic Breast Cancer
-
2019.09.04
PDF (81KB)
- Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA® (edoxaban) in Patients with Atrial Fibrillation
-
2019.08.05
PDF (97KB)
- FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor
-
2019.06.25
PDF (141KB)
- Daiichi Sankyo to transfer marketing authorization rights for four diagnostic imaging agents in Japan to GE Healthcare
-
2019.06.24
PDF (55KB)
- Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
-
2019.06.18
PDF (153KB)
- Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory FLT3-ITD AML
-
2019.06.14
PDF (173KB)
- Daiichi Sankyo Announces Launch of Oxycodone Injections “Daiichi Sankyo”
-
2019.06.03
PDF (105KB)
- Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
-
2019.06.03
PDF (163KB)
- Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
-
2019.05.23
PDF (94KB)
- Announcement Regarding Recent Media Reports
-
2019.05.17
PDF (89KB)
- Daiichi Sankyo Announces Update to H5N1 Influenza Vaccine National Project
-
2019.05.15
PDF (76KB)
- Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 Inhibitor Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
-
2019.05.15
PDF (103KB)
- FDA Oncologic Drugs Advisory Committee Votes in Favor of Daiichi Sankyo’s Pexidartinib for the Treatment of Select Patients with TGCT, a Rare, Debilitating Tumor
-
2019.05.13
PDF (193KB)
- Daiichi Sankyo Launches “MINNEBRO® Tablets” in Japan
-
2019.05.10
PDF (195KB)
- Daiichi Sankyo Announces Changes to Members of the Board and Members of the Audit and Supervisory Board
-
2019.05.08
PDF (91KB)
- Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
-
2019.04.26
PDF (78KB)
- Daiichi Sankyo Announcement Regarding Vaccine Quality Testing Methods
-
2019.04.26
PDF (100KB)
- Daiichi Sankyo Selects Lead Candidate Built on Zymeworks’ Azymetric™ Bispecific Platform
-
2019.04.25
PDF (87KB)
- Daiichi Sankyo Announces the Sale of Its Nihonbashi Building in Japan
-
2019.04.15
PDF (111KB)
- Daiichi Sankyo Launches “Tarlige® Tablets” for Pain Treatment in Japan
-
2019.04.09
PDF (55KB)
- Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from Japan MHLW
-
2019.04.05
PDF (169KB)
- Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
-
2019.04.04
PDF (115KB)
- EMA Validates Daiichi Sankyo’s Marketing Authorization Application for Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating, Non-Malignant Tumor
-
2019.03.29
PDF (98KB)
- Daiichi Sankyo Announces Chief Executive Officer (CEO) Change
-
2019.03.29
PDF (189KB)
- Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)
-
2019.03.29
PDF (192KB)
- Daiichi Sankyo Confirms Plans to Accelerate BLA Submission to U.S. FDA for [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Positive Metastatic Breast Cancer Post T-DM1
-
2019.03.27
PDF (113KB)
- Daiichi Sankyo Initiates Phase 3 Trial of Mirogabalin in Asian Post-spinal Cord Injury Neuropathic Pain Patients Including Japan
-
2019.03.25
PDF (103KB)
- Anti-epilepsy Drug VIMPAT ® for I.V. infusion 200mg Launched in Japan
-
2019.03.19
PDF (136KB)
- Daiichi Sankyo Presents Positive Results of the First Randomized, Controlled Trial of Uninterrupted Oral, Once-daily Lixiana® (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation
-
2019.03.11
PDF (153KB)
- Anti-epilepsy Drug VIMPAT® Dry syrup 10% Launched in Japan
-
2019.02.22
PDF (89KB)
- Daiichi Sankyo Announces Organizational Restructuring Effective April 1, 2019 in Japan
-
2019.02.22
PDF (121KB)
- Daiichi Sankyo Appoints New Group Corporate Officers
-
2019.02.06
PDF (88KB)
- FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating Tumor
-
2019.01.31
PDF (143KB)
- Daiichi Sankyo Announces Transfer of Daiichi Sankyo Propharma Takatsuki Plant and Company Split (Simple Absorption-type Company Split)
-
2019.01.15
PDF (271KB)
- Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
-
2019.01.10
PDF (178KB)
- Daiichi Sankyo, Mitsubishi UFJ Capital and Tokyo Institute of Technology Announce Open Innovation Research on iPS Cell-derived Insulin Producing Cells in Japan
-
2019.01.08
PDF (111KB)
- Daiichi Sankyo Announces Marketing Approval in Japan of “Tarlige® Tablets” for Pain Treatment
-
2019.01.08
PDF (91KB)
- Daiichi Sankyo Announces Approval of MINNEBRO(TM) Tablets for the Treatment of Hypertension in Japan
-
2019.01.08
PDF (175KB)
- Pediatric Dosage and Administration Approved for Anti-epileptic Drug VIMPAT® Tablets 50 mg and 100 mg
-
2019.01.07
PDF (74KB)
- Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
In order to view the PDF files, you need to have the latest version of Adobe Reader installed.
